Pfizer’s Albert Bourla explains ‘transition year’ for Covid products, with sales expected to hit a low point
On the heels of a year of record sales, Pfizer is bracing for shock as it expects revenue from Covid-19 to bottom out in 2023. That’s due to lower compliance …
Pfizer’s Albert Bourla explains ‘transition year’ for Covid products, with sales expected to hit a low point Read More